NEWSNews Releases
ISOTECHNIKA SUBSIDIARY RECEIVES CANADIAN APPROVAL TO MARKET NOVEL BREATH TEST FOR THE DETECTION OF DIABETES AND INSULIN RESISTANCE
Edmonton, Alberta, June 18, 2001 - Dr. Robert Foster, Chairman and CEO, is pleased to announce that Isodiagnostika Inc., has received a medical device license from Health Canada to market a unique breath test kit for the diagnosis of diabetes and insulin resistance under the trademark, diatest. Isodiagnostika Inc., the wholly owned diagnostic subsidiary of Isotechnika Inc., has developed this product and has recently completed all necessary clinical trials for approval in Canada.
"Diabetes is one of the fastest growing diseases in the world today. Early diagnosis is paramount in order to provide the patient with the greatest treatment options. Diatest represents a new way of diagnosing and monitoring the progress of the diabetic condition", states Joseph Koziak, Executive Vice President. "With this test, physicians will be able to diagnose the early stages of insulin resistance and Type II diabetes. We are pleased to be able to add this new patent pending test to our family of diagnostic products."
"Typical diabetic conditions begin to develop early, during the "pre-diabetic" phase of insulin resistance. Therefore the identification of persons at risk of developing Type II diabetes has taken on greater importance," states Dr. Richard Lewanczuk, Director of the Divison of Endocrinology, Faculty of Medicine, University of Alberta. "Further, the Diatest is superior to currently used laboratory criteria for the diagnosis of Type II diabetes."
Isotechnika is a life sciences company headquartered in Edmonton, Alberta, developing novel drugs and diagnostic products. Its leas compound, ISATX247 is a novel immunosuppressive drug, that can be used for prevention of organ rejection after transplatation and for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. This drug is in Phase 2 clinical trials in Canada and the United States. Based upon the studies completed to date. ISATX247 demonstrates superior efficacy and reduced toxicity when compared with presently used medications for organ transplantation such as Cyclosporine. Current annual worldwide sales of Cyclosporine are in excess of $1.4 Billion USD.
The development costs of Isotechnika's lead drug are being supported in part, by sales of the company's breath-based point-of-care diagnostic kits. These kits aid in the diagnosis of ulcers, diabetes and insulin resistance, fat malabsorption, small bowel bacterial overgrowth, and lactose intolerance. The diagnostic kits are designed to be used with the ISOMAX series of instruments developed by the company.
(Sorry for any spelling errors & pvander for the typing I could not access the hot link it did not work for me.)
Great news
Regards